Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious ...

Shares of Bristol Myers Squibb Co. slid 3.42% to $46.86 Friday, on what proved to be an all-around dismal trading session for ...

The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo ...

Discover 14 "safer" S&P 500 dividend stocks with strong free cash flow for stable payouts. Learn how they may offer 27%-53% ...

JLL helped biopharma Kardigan establish its East Coast presence in Princeton, among several recent office sector deals.

The primary exposure was a first-trimester prescription fill of nitrofurantoin, TMP-SMX, fluoroquinolones (ciprofloxacin, levofloxacin, ofloxacin), and β-lactams to treat UTI. Any congenital ...

Bristol Myers Squibb Co. annual cash flow and in depth look at BMY operating, investing, and financing activities.

Uber's Dara Khosrowshahi discusses the evolution of the 'sharing economy,' progress on rebuilding trust with local regulators ...

Bristol Myers Squibb is preparing to ship a new and possibly life-changing cancer treatment to patients across the world. The ...

ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.